Document is current

Article History

Received: 6 June 2023

Accepted: 31 October 2023

First Online: 9 November 2023

Declarations

:

: The study was approved by Zealand University Hospital and The Regional Research Registry in Region Zealand (REG-025-2021) in accordance with relevant Danish legislation and the European General Data Protection Regulation. Data from DBCG were acquired through The Danish Clinical Quality Program () with exemption from patient consent. The study was conducted in accordance with the Helsinki II declaration.

: Not applicable.

: KN, MS, and BE have declared no conflicts of interest. The remaining authors declare the following conflicts of interest: MBJ: Meeting expenses and honorarium from advisory board for Novartis; TB (2021 and 2022): Institutional grants from Pfizer, AstraZeneca, Merck, Eli Lilly, and Seattle Genetics and personal grants from Daiichi Sankyo (travel), MSD (workshop), AstraZeneca (lecture), and Pfizer (lecture); AK (2021 and 2022): Institutional grants from Pfizer, AstraZeneca, Merck, Eli Lilly, Seattle Genetics, Roche, and Novartis and personal grants from AstraZeneca (travel and advisory board), MSD (travel), Daiichi Sankyo (advisory board), Novartis (advisory board), and Seagen (advisory board); AVL: Institutional grants from AstraZeneca and personal grants from AstraZeneca (travel and honorarium from advisory board), MSD (honorarium from advisory board), and Daiichi Sankyo (travel).